Your browser doesn't support javascript.
loading
Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline.
Daamen, Marcel; Scheef, Lukas; Li, Shumei; Grothe, Michel J; Gaertner, Florian C; Buchert, Ralph; Buerger, Katharina; Dobisch, Laura; Drzezga, Alexander; Essler, Markus; Ewers, Michael; Fliessbach, Klaus; Herrera Melendez, Ana Lucia; Hetzer, Stefan; Janowitz, Daniel; Kilimann, Ingo; Krause, Bernd Joachim; Lange, Catharina; Laske, Christoph; Munk, Matthias H; Peters, Oliver; Priller, Josef; Ramirez, Alfredo; Reimold, Matthias; Rominger, Axel; Rostamzadeh, Ayda; Roeske, Sandra; Roy, Nina; Scheffler, Klaus; Schneider, Anja; Spottke, Annika; Spruth, Eike Jakob; Teipel, Stefan J; Wagner, Michael; Düzel, Emrah; Jessen, Frank; Boecker, Henning.
Afiliação
  • Daamen M; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Scheef L; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Li S; Department for Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
  • Grothe MJ; RheinAhrCampus, University of Applied Sciences Koblenz, Remagen, Germany.
  • Gaertner FC; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Buchert R; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Buerger K; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
  • Dobisch L; Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Drzezga A; Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Essler M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Ewers M; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.
  • Fliessbach K; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Herrera Melendez AL; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Hetzer S; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Janowitz D; Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Jülich, Germany.
  • Kilimann I; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
  • Krause BJ; Institute for Clinical Radiology, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Lange C; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Laske C; Department of Neurodegenerative Disease and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Munk MH; Institute of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Peters O; Berlin Center of Advanced Neuroimaging, Charité -Universitätsmedizin Berlin, Berlin, Germany.
  • Priller J; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilian University Munich, Munich, Germany.
  • Ramirez A; German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Germany.
  • Reimold M; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Rominger A; Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, Germany.
  • Rostamzadeh A; Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Roeske S; German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany.
  • Roy N; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
  • Scheffler K; German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany.
  • Schneider A; Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
  • Spottke A; Institute of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Spruth EJ; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Teipel SJ; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Wagner M; Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Düzel E; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
  • Jessen F; University of Edinburgh and UK Dementia Research Institute, Edinburgh, UK.
  • Boecker H; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
J Alzheimers Dis ; 95(3): 1013-1028, 2023.
Article em En | MEDLINE | ID: mdl-37638433
BACKGROUND: Atrophy of cholinergic basal forebrain (BF) nuclei is a frequent finding in magnetic resonance imaging (MRI) volumetry studies that examined patients with prodromal or clinical Alzheimer's disease (AD), but less clear for individuals in earlier stages of the clinical AD continuum. OBJECTIVE: To examine BF volume reductions in subjective cognitive decline (SCD) participants with AD pathologic changes. METHODS: The present study compared MRI-based BF volume measurements in age- and sex-matched samples of N = 24 amyloid-positive and N = 24 amyloid-negative SCD individuals, based on binary visual ratings of Florbetaben positron emission tomography (PET) measurements. Additionally, we assessed associations of BF volume with cortical amyloid burden, based on semiquantitative Centiloid (CL) analyses. RESULTS: Group differences approached significance for BF total volume (p = 0.061) and the Ch4 subregion (p = 0.059) only, showing the expected relative volume reductions for the amyloid-positive subgroup. There were also significant inverse correlations between BF volumes and CL values, which again were most robust for BF total volume and the Ch4 subregion. CONCLUSIONS: The results are consistent with the hypothesis that amyloid-positive SCD individuals, which are considered to represent a transitional stage on the clinical AD continuum, already show incipient alterations of BF integrity. The negative association with a continuous measure of cortical amyloid burden also suggests that this may reflect an incremental process. Yet, further research is needed to evaluate whether BF changes already emerge at "grey zone" levels of amyloid accumulation, before amyloidosis is reliably detected by PET visual readings.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva / Prosencéfalo Basal Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva / Prosencéfalo Basal Idioma: En Ano de publicação: 2023 Tipo de documento: Article